Summary & Overview
HCPCS Q4104: Integra Bilayer Matrix Wound Dressing, per cm
HCPCS Level II code Q4104 denotes the Integra bilayer matrix wound dressing billed per square centimeter as an add-on, listed separately in addition to a primary procedure. This code captures use of a commercially manufactured bilayer biomaterial applied to manage complex wounds, support dermal regeneration, and protect wound beds. Nationally, use of specific product-level HCPCS codes affects coding accuracy, reimbursement pathways, and supply management for wound-care programs.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication provides payer coverage context and benchmarking where available, and highlights clinical and billing considerations related to add-on product coding.
Readers will learn what the code represents, typical sites of service and clinical contexts for Integra bilayer matrix application, and what to expect in payer coverage patterns and billing practice. The report summarizes available benchmarks, common modifier practices, and relevant policy updates when present. Data not available in the input is noted explicitly where applicable.
Billing Code Overview
HCPCS Level II code Q4104 describes Integra bilayer matrix wound dressing (BMWD), billed per square centimeter. This code is an add-on, list separately entry used when a bilayer wound dressing product is applied in conjunction with a primary wound procedure.
Service Type: Advanced wound care product application / biomaterial wound dressing
Typical Site of Service: Outpatient wound care clinics, hospital outpatient departments, ambulatory surgical centers, and other settings where advanced wound dressings are applied
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a full-thickness or complex partial-thickness skin loss after excision of chronically non-healing wounds (for example, diabetic foot ulcer, venous stasis ulcer, pressure ulcer, or traumatic soft-tissue loss) requiring placement of a biologic bilayer matrix wound dressing. The procedure is performed in an outpatient wound clinic, ambulatory surgery center, or inpatient operating room depending on wound complexity and patient comorbidities. Clinical workflow: wound assessment and debridement are performed first (sharp, mechanical, or enzymatic) with hemostasis achieved; wound measurements are documented in square centimeters; Q4104 is applied as an add-on dressing per square centimeter over the prepared wound bed and secured; dressings are monitored with scheduled follow-up visits for graft take, infection surveillance, and dressing changes; adjunctive therapies (offloading, compression, negative-pressure wound therapy) are used as clinically indicated.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural service | Use when work is substantially greater than typical due to extensive debridement or complex wound preparation preceding application of the bilayer matrix. |